Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. The company’s VoyageR AI platform integrates computational methods to drug traditionally undruggable RNA targets.

Development 241

Development RNA Gene Therapy Genetics 241

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. There has been a flurry of other licensing and M&A deals in the RNA space since the start of the pandemic, headlined by Sanofi’s $3.2

RNA 52

RNA Immune Response Vaccination Vaccine 52

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. The first identifies the 3D RNA motifs.

RNA 52

RNA Protein Bioavailability DNA 52

BioSpace

SEPTEMBER 8, 2021

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

RNA 80

RNA Licensing Licensing Life Science 80

BioTech 365

JANUARY 20, 2021

Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine — Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase … Continue reading → (..)

Licensing 40

Licensing Licensing Vaccination Vaccine 40

XTalks

AUGUST 9, 2022

Innova Medical Group, the world’s largest COVID-19 test provider, has secured the licensing rights for commercializing a new COVID-19 testing technology developed at the University of Birmingham. Innova Medical Group, which secured the licensing rights for the test, is the world’s largest provider of lateral flow tests.

Licensing 98

Licensing Licensing DNA RNA 98

Pharmaceutical Technology

AUGUST 1, 2022

In March, the company entered a licensing agreement with Serum Institute of India (SII) to expedite access to messenger RNA products in emerging markets worldwide. The human health product candidates of GreenLight are currently in the pre-clinical stage.

Vaccination 245

Vaccination Vaccine Development RNA 245

BioSpace

OCTOBER 5, 2021

Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.

Gene Therapy 85

Gene Therapy RNA Gene Licensing 85

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Gene Therapy 52

Gene Therapy Licensing Licensing Gene 52

Pharmaceutical Technology

NOVEMBER 10, 2022

In 2016, it was licensed by the company to Amgen. Royalty Pharma founder and CEO Pablo Legorreta said: “We are delighted to partner with Arrowhead, a leader in RNA interference (RNAi) therapeutics, to help them achieve their strategic objectives and fund their attractive pipeline.

RNA 130

RNA Sales Clinical Trials Clinical Trials 130

BioSpace

AUGUST 2, 2021

Shares of Autolus were up more than 12% this morning after it forged an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.

RNA 82

RNA Licensing Licensing Development 82

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

XTalks

JANUARY 3, 2024

Novartis and Voyager Therapeutics have struck a licensing deal that will see Novartis pay Voyager $100 million upfront to develop gene therapy candidates targeting Huntington’s disease (HD) and spinal muscular atrophy (SMA). The total value of the deal could potentially reach $1.2

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.

RNA 105

RNA Genetics Dermatology Antibody 105

Drug Discovery World

MARCH 3, 2023

Under the terms of the agreement SiSaf has an exclusive option to acquire a worldwide license to a patent by the University. miRNAs are involved in the regulation of various physiological and pathological processes.

Development 52

Development RNA Drug Delivery Regulation 52

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The system comprises the Cas9 enzyme and a guide RNA. The gene-editing technology allows for precise, directed changes to genomic DNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. This delivery technology protects the messenger RNA (mRNA) payload after administration allowing it to be safely and effectively delivered into cells.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. In 2019 the Danish company also licensed a preclinical-stage, small-molecule candidate for NASH from Japan’s UBE.

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

JULY 6, 2021

The small interfering RNA (siRNA) therapy has already been approved in Europe as Leqvio , and the FDA’s rejection was not caused by any issues with its efficacy or safety, according to Novartis. Novartis added inclisiran to its pipeline after buying The Medicines Company, which had licensed the drug from Alnylam, for $9.7

RNA 105

RNA Manufacturing Sales Marketing 105

pharmaphorum

JANUARY 7, 2022

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. The new agreement comes just days after AZ closed a $3.1

Antibody 116

Antibody Licensing Licensing Protein 116

pharmaphorum

JANUARY 5, 2023

Nonetheless, Moderna has previously been involved in licensing deals to advance its technology. Most recently, of course, Moderna developed one of the earliest vaccines against the COVID-19 pandemic to be authorised and approved.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

pharmaphorum

JANUARY 22, 2021

Veklury is currently the only antiviral drug licensed for the treatment of COVID-19 and works by interfering with a polymerase enzyme central to the production of viral RNA particles.

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

pharmaphorum

MAY 11, 2022

The pharma group will provide funding for the research in return for exclusive license options on the programmes. billion takeover of gene-silencing specialist Dicerna Pharma last year, another deal aimed at extending its R&D capabilities by bolting on a new platform technology – in this case RNA interference (RNAi) drugs.

Gene Silencing 126

Gene Silencing Medicine RNA Licensing 126

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Ribometrix has presented that many RNAs implicated in disease comprise structural pockets amenable to targeting with small molecules.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

pharmaphorum

MAY 26, 2022

His work on a technique known as Hijack RNA, which tricks viruses into killing the cells they infect, underpins Enochian’s antiviral pipeline. ” CEO Mark Dybul added that “the profound potential of the scientific ideas, and the promising preclinical and in certain cases clinical data have not changed.”

Gene Expression 105

Gene Expression RNA Licensing Licensing 105

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. The major difference between siRNAs and microRNAs is that the former are very specific to one messenger RNA target, while the latter can have multiple targets.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

pharmaphorum

JANUARY 12, 2021

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology.

RNA 95

RNA Production Development Pharma Companies 95

pharmaphorum

OCTOBER 27, 2020

Merimepodib – originally developed by Vertex Pharma – is an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMDPH), which is required for the synthesis of viral RNA. Merimepodib is the subsidiary’s primary asset, and the biotech now says it is to offers to acquire or license the drug. Image credit: Rocky Mountain Labs/NIH.

Drug Trials 98

Drug Trials Trials Drugs Contract Manufacturing 98

Drug Discovery World

DECEMBER 12, 2023

KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT.

RNA 52

RNA In-Vivo Genotype Genetics 52

pharmaphorum

FEBRUARY 19, 2021

Novavax licensed its NVX-CoV2373 technology to SII with no upfront, milestone or technology transfer payments so that the vaccine can be manufactured and supplied cheaply to poorer countries. Novavax has created a global supply network to ensure there can be adequate and equitable supply of NVX-CoV2373 across the globe.

Vaccination 80

Vaccination Vaccine Manufacturing RNA 80

pharmaphorum

DECEMBER 23, 2021

The first-in-class, small interfering RNA (siRNA) therapy for cholesterol lowering inhibiting PCSSK9 – the same target as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – but after a lead-in period is dosed only twice a year rather than every month. It has a long way to go.

Drugs 105

Drugs Sales Antibody FDA Approval 105

pharmaphorum

SEPTEMBER 2, 2022

Novo Nordisk licensed rights to EPI01 from EpiDestiny in 2018, paying $400 million for rights to the drug in haemaglobinopathies, while the biotech retained rights in oncology. billion acquisition of RNA interference specialist Dicerna, which closed earlier this year. It follows Novo Nordisk’s $3.3

RNA 52

RNA Licensing Licensing Trials 52

The Pharma Data

MARCH 8, 2021

Week 96 findings reinforce the primary (proportion of participants with plasma HIV-1 RNA ?50 50 c/mL at Week 48 (Snapshot, ITT-E)), and secondary endpoints (proportion of participants with plasma HIV-1 RNA ?50 Week 48 primary endpoint (proportion of participants with plasma HIV-1 RNA ?50

RNA 52

RNA Branding Development Licensing 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. million, compared to $1.1 million for the same period in 2022.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

NOVEMBER 2, 2022

CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

pharmaphorum

JUNE 1, 2022

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk factor for cardiovascular disease – that was sustained over 48 weeks of follow-up.

Gene Silencing 59

Gene Silencing Drugs Medicine RNA 59